ArticleApplied microbiology and biotechnology2025
Generation of novel polyclonal antibodies against Mycobacterium tuberculosis lipoarabinomannan, EspB, and Mtb8.
Article in Applied microbiology and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Breaking the barrier: from biosynthetic inhibition to multidimensional modulation of the mycobacterial cell wall in tuberculosis therapy.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The unique cell wall of Mycobacterium tuberculosis (Mtb) creates a barrier to hydrophilic drugs, which is crucial for its survival and pathogenicity. However, the immune reactivity elicited by its components remains incompletely understood. We aimed to assess the antibody responses induced by Mtb H37Rv cell wall components and to develop and characterize antigen-specific polyclonal antibodies (pAbs). Rabbits were immunized with these components. Immune serum reactivity was tested against various Mtb antigens. Specific polyclonal antibodies (pAbs) were purified by affinity chromatography. The results showed that immune serum reacted with lipoarabinomannan (LAM), ESAT-6 secretion system-1 (Esx-1) secreted protein B (EspB), and Mtb8, but showed no reactivity with other tested Mtb antigens. LAM-, EspB-, or Mtb8-specific pAbs were subsequently affinity-purified. The affinity-purified LAM pAb, EspB pAb, and Mtb8 pAb each demonstrated high specificity and sensitivity, showing no cross-reactivity with non-target antigens. They recognized antigens in culture supernatants and cells from diverse mycobacterial strains, including both slow-growing mycobacteria (SGM) and rapid-growing mycobacteria (RGM). In a sandwich ELISA using LAM pAb as the capture antibody and biotinylated LAM-specific monoclonal Abs (BJRbL01-Bio, BJRbL03-Bio, BJRbL20-Bio, BJRbL52-Bio, or BJRbL76-Bio) as detection antibodies, the assay detected SGM but did not react with RGM species. EspB pAb recognized EspB in both cell lysate and culture supernatant fractions, where full-length and mature EspB are predominantly found, respectively. Mtb8 pAb reacted with monomeric and polymeric forms of Mtb8. In conclusion, we successfully generated novel pAbs against LAM, EspB, and Mtb8, providing promising research tools for investigating these critical molecules. KEY POINTS: Rabbit antibodies against Mtb H37Rv cell wall components target LAM, EspB, and Mtb8 Novel LAM-, EspB-, and Mtb8-specific pAbs were generated and characterized Broad mycobacterial reactivity and specific target detection confirm pAb utility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.